Table 3 : The growth and potential of human antiviral monoclonal antibody therapeutics : Nature Biotechnology

From the following article

The growth and potential of human antiviral monoclonal antibody therapeutics

Wayne A Marasco & Jianhua Sui

Nature Biotechnology 25, 1421 - 1434 (2007) Published online: 7 December 2007

doi:10.1038/nbt1363

Table 3. Commercial development of antiviral mAbs^{^a}

Next tablePrevious tableFigures and tables index

	Virus	Stage of development	mAb	Isoform	Target	Development technology	Company (location)	Indication	Reference
^aInformation collected from medical literature, manufacturers' websites and press releases.
^bFor prevention and treatment of RSV infection in high risk pediatric patients, the current recommendations are Palivizumab at 15 mg/kg of body weight as an intramuscular injection monthly throughout the RSV season, generally November through April in North America. In addition, the American Academy of Pediatrics (AAP) currently recommends palivizumab prophylaxis for children who present to the emergency department with bronchiolitis.
^chttp://www.crucell.com/R_and_D-Clincal_Development-Rabies_Antibody_Product.
^dWNV establishes persistent infection in central nervous system. Neurons are infected, and destruction of bystander nerve cells and immune-mediated damage contribute to neurologic disease. Different clinical syndromes of WNV neuroinvasive disease have been described¹²⁴.
^ehttp://www.progenics.com/pro140.cfm
^fhttp://www.peregrineinc.com/content.php?mi=MTk=
^ghttp://www.peregrineinc.com/content.php?mi=Mzg= and http://www.rxpgnews.com/article_4411.shtml
Acute cytopathic	RSV	Approved	Synagis (Palivizumab; MEDI-493)	IgG1	Glycoprotein F	Humanized	MedImmune	Prophylaxis in high risk infants^{^b}	111
	RSV	Phase 3	Numax (Motavizumab; MEDI-524)	IgG1	Glycoprotein F	Humanized and affinity matured from palivizumab	MedImmune	Prophylaxis in high risk infants	53 54 112
	Rabies	Phase 1	CR4098	IgG1	Glycoprotein antigenic site III	Immune Ab phage display library	Crucell (Leiden, The Netherlands)	Post-exposure prophylaxis; use in combination	57^{^c}
			CR 57		Glycoprotein antigenic site I	EBV immortalization
	Rabies	Preclinical (clinical trials to start in India in 2008)	17C7	IgG1	Glycoprotein, either antigenic site III or minor site A	Transgenic HuMab-Mouse (Medarex)	Massachusetts Biologic Laboratories	Post-exposure prophylaxis	10
	WNV^{^d}	Phase I	hE16 (MGAWN1)	IgG1	Envelope (E) protein, domain III	Humanized	Macrogenics (Rockville, MD, USA)	A potential therapy for diseases associated with severe West Nile Virus infection	113
	WNV	Pre-clinical	CR4374	IgG1	E protein, domain III	Immune human Ab phage display library	Crucell	Protected mice from infection	114
	SARS	Pre-clinical	CR3014 CR3022	IgG1	S1-RBD	Immune phage display Ab library	Crucell	CR3014 protected ferrets CR3022 neutralized CR3014 escape viruses; mixture of CR3014/3022 showed synergistic effect	116
Acute cytopathic/latent reactivation	CMV	Phase 2	TI-23	IgG1	Envelope glycoprotein gb	Human hybridoma	Teijin Pharma (Tokyo, Japan)	Treatment of CMV Retinitis in HIV individuals / CMV pneumonia in bone marrow transplantation—individuals	117
	CMV	Information not available	HCMV37	IgG1	Envelope glycoprotein gb	Humanized	Scotgen Biopharmaceuticals (Aberdeen, UK; closed doors in 1997)	HCMV infections in immunocompromised individuals	118
	EBV	Phase 2	Rituxan (Rituximab)	IgG1	CD20	Chimeric	Genentech (S. San Francisco, CA, USA)	Treatment, EBV-associated post-transplant lymphoproliferative disorders (interstitial pneumonia)	119
	VZV	Preclinical	TI-57	IgG1	Envelope glycoprotein III	Human hybridoma	Teijin Pharma	Treatment of Varicella Zoster	120
Chronic, non-cytopathic	HIV	Phase 2	TNX-355	IgG4	CD4	Humanized	Genentech	Treatment	121
	HIV	Phase 1	KD-247	IgG1	gp120-V3 tip	Humanized	Kaketsuken-Chemo-Sero-Therapeutic Research Institute (Kumamoto, Japan)	Treatment	84
	HIV	Phase 1	PRO140	IgG4	CCR5	Humanized	Progenics Pharmaceuticals (Tarrytown, NY, USA)	Treatment	84
	HIV	Phase 1 Preclinical	HGS004 HGS101	IgG4 IgG1	CCR5	Abgenix XenoMouse technology	Human Genome Sciences (Rockville, MD, USA)	Treatment 5.5-fold greater potency and a broader range of activity against HIV-1 viral strains than HGS004	84^{^e}
	HIV	Preclinical	Tarvacin (Bavituximab)	IgG1	Aminophospholipids exposed on the surface of cells	Chimeric	Peregrine Pharmaceuticals (Tustin, CA, USA)	Treatment	^{^f}
	HCV	Phase 1	Tarvacin (Bavituximab)	IgG1	Aminophospholipid, binds to phospholipids which are derived from the host cell	Chimeric	Peregrine Pharmaceuticals	Treatment of HCV and HIV co-infection	^{^g}
	HCV	Phase 1	HepeX-C (XTL-6865, cocktail of mAbs AB68 and AB65)	IgG1	Envelope protein E2	AB68, human hybridoma; AB65, EBV immortalization	XTL Biopharmaceuticals (Rehovot, Israel)	Treatment	122
	HCV	Preclinical	HuMax-HepC	IgG1	Envelope protein E2	EBV immortalization	Genmab (Copenhagen)	Prophylaxis	123

Next tablePrevious tableFigures and tables index

BACK TO ARTICLE

Table 3

From the following article

Table 3. Commercial development of antiviral mAbsa

Table 3. Commercial development of antiviral mAbs^{^a}